Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows years of setbacks and delays in getting the ...

The Food and Drug Administration granted approval Tuesday to a closely watched Alzheimer’s drug, concluding that the benefits ...

The FDA approved the experimental Alzheimer's drug donanemab. The drug will be sold under the brand name Kisunla.

The FDA has approved a new medication for people with Alzheimer’s disease. Eli Lilly’s Kisunla (donanemab) is a once-monthly ...

Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic ...

Our Director of Research responds to news that the FDA has approved new Alzheimer's disease drug donanemab in the US.

The regulatory greenlight comes less than a month after an FDA advisory committee unanimously backed the drug for approval.

The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of ...

The FDA has approved the anti-amyloid donanemab for early symptomatic Alzheimer's, which includes MCI or mild dementia stage of disease, with confirmed amyloid pathology.

A new treatment that could slow Alzheimer’s disease has been approved by the Food and Drug Administration. The drug Donanemab ...

The Food and Drug Administration (FDA) on Tuesday approved donanemab, Eli Lilly’s monoclonal antibody drug for early-stage ...

Donanemab (Kisunla), a new drug to treat Alzheimer's disease, was approved by the U.S. Food and Drug Administration on ...